600 patients67,035 observations120 daysLIVE

Patient P-01438

Synthetic patientNBL-101 · Day 112 · 35–44 · M · baseline S06Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 46 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 45%, therapy response 44 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 53 (HRV −10 ms, resting HR +5 bpm, sleep −0.6 h, gi toxicity +29, inflammatory load +16); the side effect would have been reported on day 60 — 7 days of warning.

Still taking it?

5 of 8 scheduled doses in the last 60 days are biologically confirmed (63%). Dose signature: resting HR +7 bpm, HRV −9 ms.

last 8 doses · green confirmed · amber logged only · red missed
Plan for this patient
not yet offeredstrongowner · Study nursereview day 115Human Model →
Next action
ME-01 Monitoring Escalation
71% probability of improvement
Kept if

100% of 284 similar trajectories improved after ME-01; if this one does, discontinuation risk is expected to fall from 60% to ~44%. Keeping fat low is worth 4.4 GI points a day on its own. Losing this patient costs €57k; the intervention costs €180.

Daily to-dos in the companion
  • 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊Electrolyte solution, one sachet after any loose stool
Adherence
43% stable

Dose is being missed; nothing else works until this is fixed.

Changes the plan if

GI burden above 62 for 3 days within the onset window

LLIFE OS insight
grounded · add an LLM key for prose

P-01438 is on day 112 of NBL-101 (EC-03, baseline S06): response declining, tolerance deteriorating, GI stable. Over 14 days response moved -8 and GI -2; discontinuation risk is 60%. The state is between basins, heading towards failing, after diverging from the model on day 53.

Biology sets the gain: IL6 high-expression variant, Low butyrate capacity, Low microbial diversity, Cluster EC-03 (high response / high intolerance), Adherence < 60%; butyrate capacity 28/100, diversity 2.1. Pushing it down: Enterococcus faecium 15.941% (LPS load) (-32.6), Low butyrate capacity (-27.5), 6 keystone species absent (-20.6). Pulling it up: Dietary Support Protocol NP-02 (+32.1), GI Support Protocol GI-04 (+30.5). From the daily log: fat +4.4 GI next day, simple carbs +3.4 GI next day, spicy +3.4 GI next day.

Past actions: NP-02 on day 32 → improved (17%); GI-04 on day 51 → improved (18%).

Next: ME-01 — 100% of 284 similar trajectories improved, 71% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.

Therapy response
Declining
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
60%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S06
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 GI symptom burden −17% vs expectedDietary Support Protocol NP-02
  5. Day 48 Tolerance state changedUnstable → Improving
  6. Day 50 GI-04 recommendedGI Support Protocol GI-04
  7. Day 51 Patient acceptedStarted GI-04 in the companion
  8. Day 53 Trajectory diverged from predictionObserved response fell below the model's expected path.
  9. Day 59 GI symptom burden −18% vs expectedGI Support Protocol GI-04
  10. Day 65 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 53.

Primary contributors, last 14 days
  • Toxicity+9
  • Treatment adherence-8
  • Inflammatory activity-3
  • GI instability-2

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: symptom burden −17%
  • GI Support Protocol GI-04Day 50
    Result: symptom burden −18%
LIFE OS recommendation
71%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Daily trackers

Asset settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
54.4/100
worsening · +8.3 vs previous 14 d
Toxicity
Blood
45.7/100
improving · -3.3 vs previous 14 d
Sleep quality
Wearable
12.1/100
worsening · -3.8 vs previous 14 d
Energy level
Daily log
2.7/10
worsening · -0.4 vs previous 14 d
Stress level
Daily log
6/10
stable · +0.0 vs previous 14 d
Steps
Wearable
4,693
stable · -265 vs previous 14 d
Adherence
Companion
42.5 %
stable · -0.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 30 from the failing basin, 57 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 67 similar · onset 3 d · confidence 59%
  • SC-12 Supportive Compound
    65% improved among 46 similar · onset 6 d · confidence 59%
  • CR-01 Clinician Review
    100% improved among 9 similar · onset 5 d · confidence 59%
Would not help
  • Keep fat low
    GI +4.4 next day on high-intake days · n 21
  • Keep simple carbs low
    GI +3.4 next day on high-intake days · n 19
  • Keep spicy low
    GI +3.4 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +4.4detractor · 95%
  • Simple carbohydrates
    +3.4detractor · 78%
  • Spicy / capsaicin
    +3.4detractor · 68%
  • Insoluble fibre
    +2.3no signal · 46%
  • Histamine load
    +0.9no signal · 15%
  • Alcohol
    -0.3no signal · 15%

DeepGene damage signature

The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

Damage score · retest day 90
85/100
vs baseline (day 0)
+11
1 improved · 10 worsened
synthetic signature · consistent with this patient's biology
  • 4 opportunists above range: Klebsiella pneumoniae, Enterococcus faecium, Streptococcus gallolyticus
  • 6 keystone species absent
  • Shannon 1.63 (expected ≥ 3)
  • 10 resistance genes
  • Host DNA fragmentation atypical
  • Tissue recycling index 64
Pathogens / opportunists4/5
from 2
Keystone species6/8
from 4
Diversity2/2
Metabolic modules0/4
Vitamin synthesis5/7
from 4
Oral translocation1/1
Host DNA1/1
Tissue recycling1/1
Central mechanisms2/2
from 1
Virulence factors6/6
from 4
Antibiotic resistance genes10/10
from 8
Genetic predisposition2/2
Opportunists above range
Enterococcus faecium 15.941% AR
Klebsiella pneumoniae 9.564% AR
Streptococcus gallolyticus 3.188% AR
Clostridioides difficile 3.188% AR
Keystone species absent
Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale, Faecalibacterium prausnitzii
Capacity
Shannon 1.63 · butyrate 323 CPM · SCFA 593
5 vitamins below
Host & mechanisms
host DNA fragmentation atypical
tissue recycling 64/100
oral translocation 7.22% AR
molecular_mimicry above
estrobolome above
10 resistance genes · 6 virulence factors

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 28/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 51
    • WearableHRV 30 ms, trending down
  • Mucosal barrier integrity 60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 54 and rising
    • WearableSleep 5.6 h, below personal baseline
  • Drug metabolism and exposure 20
    • BloodToxicity index 46
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.1 · butyrate capacity 28/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
27 ms
Sleep
5.6 h
Steps
6,705
Resting HR
70 bpm
Daily log: GI score 54, nutritional resilience 42, adherence 43.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0158258%S07GI-04improved43
P-0146554%S14NP-02improved47
P-0177253%S14SC-12improved46
P-0170952%S14NP-02improved42
P-0164751%S14GI-04improved42
P-0179751%S14NP-02improved45
P-0184251%S14NP-02improved44
P-0136850%S15GI-04improved49
P-0139350%S10GI-04improved50
P-0140050%S14GI-04improved49
P-0141350%S14GI-04improved47
P-0154450%S14SC-12improved46